Brief: Apyx Medical Corporation Q2 sales USD 13.569 million
10/08/2023 22:09
Aug 10 (Reuters) - Apyx Medical Corporation Q2 adjusted EBITDA USD -1.623 million. * Q2 pretax profit USD -953 thousand * Q2 income from operations USD -1.235 million * Q2 net income USD -1.019 million * Q2 sales USD 13.569 million vs. IBES estimate USD 14.3 million * Q2 gross margin 68.4%
Recent news on Apyx Medical
See all newsBrief: Apyx Medical - Appoints Stavros Vizirgianakis As Executive Chairman Effective June 11, 2026
Brief: Apyx Medical Corporation Receives Expanded FDA 510(K) Clearance Adding Power Liposuction Capability To AYON Body Contouring System™
Apyx Medical Q1 revenue beats estimates, outlook raised
Preview: Weight-loss revolution sparks new appetite for aesthetics firms
Apyx Medical Q4 revenue beats on Surgical Aesthetics unit strength